Which has better earnings & valuation, MBOT or BEAT?

Microbot Medical is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Microbot Medical N/A N/A -$13.14M -$0.24 N/A HeartBeam N/A N/A -$21.01M -$0.56 N/A

Is MBOT or BEAT more profitable?

Microbot Medical's return on equity of -21.32% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Microbot Medical N/A -21.32% -20.31% HeartBeam N/A -1,034.04% -434.40%

Do analysts rate BEAT or KEQU?

HeartBeam currently has a consensus target price of $4.00, indicating a potential upside of 578.20%. Given HeartBeam's stronger consensus rating and higher possible upside, research analysts clearly believe HeartBeam is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartBeam 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67 Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LUNG or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% HeartBeam N/A -1,034.04% -434.40%

Is OM or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Outset Medical's net margin of -63.06%. Outset Medical's return on equity of -58.06% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Outset Medical -63.06% -58.06% -27.68% HeartBeam N/A -1,034.04% -434.40%

Is HYPR or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -99.81% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -99.81% -64.95% HeartBeam N/A -1,034.04% -434.40%

HeartBeam (BEAT) Competitors

$0.59 +0.02 (+3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$0.59 +0.00 (+0.37%)

As of 06:06 PM Eastern

Compare

BEAT vs. MBOT, KEQU, LUNG, OM, and HYPR

Should you buy HeartBeam stock or one of its competitors? HeartBeam's main competitors and comparable companies include Microbot Medical (MBOT), Kewaunee Scientific (KEQU), Pulmonx (LUNG), Outset Medical (OM), and Hyperfine (HYPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartBeam compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Microbot Medical had 4 more articles in the media than HeartBeam. MarketBeat recorded 6 mentions for Microbot Medical and 2 mentions for HeartBeam. HeartBeam's average media sentiment score of 0.93 beat Microbot Medical's score of 0.29 indicating that HeartBeam is being referred to more favorably in the news media.

Company	Overall Sentiment
Microbot Medical	Neutral
HeartBeam	Positive

Microbot Medical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.78, meaning that its stock price is 178% less volatile than the broader market.

Microbot Medical presently has a consensus target price of $6.63, suggesting a potential upside of 294.35%. HeartBeam has a consensus target price of $4.00, suggesting a potential upside of 578.20%. Given HeartBeam's higher possible upside, analysts plainly believe HeartBeam is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Microbot Medical is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.24	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

Microbot Medical's return on equity of -21.32% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.32%	-20.31%
HeartBeam	N/A	-1,034.04%	-434.40%

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 7.8% of HeartBeam shares are held by institutional investors. 4.7% of Microbot Medical shares are held by company insiders. Comparatively, 18.0% of HeartBeam shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Microbot Medical beats HeartBeam on 9 of the 14 factors compared between the two stocks.

How does HeartBeam compare to Kewaunee Scientific?

HeartBeam (NASDAQ:BEAT) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 14.1% of Kewaunee Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kewaunee Scientific has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
Kewaunee Scientific	$282M	0.37	$9.62M	$3.22	11.35

Kewaunee Scientific has a net margin of 3.41% compared to HeartBeam's net margin of 0.00%. Kewaunee Scientific's return on equity of 14.10% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
Kewaunee Scientific	3.41%	14.10%	5.55%

HeartBeam currently has a consensus target price of $4.00, indicating a potential upside of 578.20%. Given HeartBeam's stronger consensus rating and higher possible upside, research analysts clearly believe HeartBeam is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartBeam has a beta of -0.78, indicating that its share price is 178% less volatile than the broader market. Comparatively, Kewaunee Scientific has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

In the previous week, HeartBeam and HeartBeam both had 2 articles in the media. HeartBeam's average media sentiment score of 0.93 equaled Kewaunee Scientific'saverage media sentiment score.

Company	Overall Sentiment
HeartBeam	Positive
Kewaunee Scientific	Positive

Summary

Kewaunee Scientific beats HeartBeam on 9 of the 14 factors compared between the two stocks.

How does HeartBeam compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

HeartBeam has a net margin of 0.00% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
HeartBeam	N/A	-1,034.04%	-434.40%

In the previous week, Pulmonx and Pulmonx both had 2 articles in the media. Pulmonx's average media sentiment score of 0.93 equaled HeartBeam'saverage media sentiment score.

Company	Overall Sentiment
Pulmonx	Positive
HeartBeam	Positive

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 7.8% of HeartBeam shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 18.0% of HeartBeam shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pulmonx presently has a consensus target price of $7.67, suggesting a potential upside of 254.94%. HeartBeam has a consensus target price of $4.00, suggesting a potential upside of 578.20%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts clearly believe HeartBeam is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Pulmonx has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, HeartBeam has a beta of -0.78, indicating that its stock price is 178% less volatile than the broader market.

HeartBeam has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	1.03	-$54M	-$1.16	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

Summary

HeartBeam beats Pulmonx on 9 of the 14 factors compared between the two stocks.

How does HeartBeam compare to Outset Medical?

Outset Medical (NASDAQ:OM) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Outset Medical has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.78, indicating that its stock price is 178% less volatile than the broader market.

In the previous week, Outset Medical had 5 more articles in the media than HeartBeam. MarketBeat recorded 7 mentions for Outset Medical and 2 mentions for HeartBeam. HeartBeam's average media sentiment score of 0.93 beat Outset Medical's score of 0.12 indicating that HeartBeam is being referred to more favorably in the news media.

Company	Overall Sentiment
Outset Medical	Neutral
HeartBeam	Positive

7.8% of HeartBeam shares are held by institutional investors. 2.5% of Outset Medical shares are held by insiders. Comparatively, 18.0% of HeartBeam shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Outset Medical currently has a consensus target price of $10.00, suggesting a potential upside of 135.29%. HeartBeam has a consensus target price of $4.00, suggesting a potential upside of 578.20%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts clearly believe HeartBeam is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

HeartBeam has lower revenue, but higher earnings than Outset Medical. HeartBeam is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outset Medical	$119.48M	0.67	-$81.65M	-$4.09	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

HeartBeam has a net margin of 0.00% compared to Outset Medical's net margin of -63.06%. Outset Medical's return on equity of -58.06% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outset Medical	-63.06%	-58.06%	-27.68%
HeartBeam	N/A	-1,034.04%	-434.40%

Summary

HeartBeam beats Outset Medical on 10 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -99.81% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-99.81%	-64.95%
HeartBeam	N/A	-1,034.04%	-434.40%

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 18.0% of HeartBeam shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Hyperfine had 6 more articles in the media than HeartBeam. MarketBeat recorded 8 mentions for Hyperfine and 2 mentions for HeartBeam. HeartBeam's average media sentiment score of 0.93 beat Hyperfine's score of 0.44 indicating that HeartBeam is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperfine	Neutral
HeartBeam	Positive

Hyperfine has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.78, suggesting that its share price is 178% less volatile than the broader market.

Hyperfine presently has a consensus target price of $1.74, indicating a potential upside of 94.50%. HeartBeam has a consensus target price of $4.00, indicating a potential upside of 578.20%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

HeartBeam has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	7.78	-$35.57M	-$0.38	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

Summary

Hyperfine and HeartBeam tied by winning 8 of the 16 factors compared between the two stocks.

Get HeartBeam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAT vs. The Competition

Export

Metric	HeartBeam	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.74M	$5.85B	$7.03B	$13.08B
Dividend Yield	N/A	1.76%	2.58%	10.74%
P/E Ratio	-1.05	25.27	270.65	25.25
Price / Sales	N/A	69.87	641.14	104.62
Price / Cash	N/A	33.59	70.59	50.58
Price / Book	9.83	5.90	13.24	6.24
Net Income	-$21.01M	$148.67M	$3.45B	$347.70M
7 Day Performance	15.56%	3.09%	2.03%	1.92%
1 Month Performance	2.06%	3.13%	1.07%	1.05%
1 Year Performance	-50.85%	8.30%	67.58%	19.53%

HeartBeam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAT HeartBeam	3.6014 of 5 stars	$0.59 +3.1%	$4.00 +578.2%	-52.5%	$32.74M	N/A	N/A	1,700	Earnings Report Gap Up
MBOT Microbot Medical	2.6147 of 5 stars	$1.73 +3.0%	$6.63 +283.0%	-44.4%	$116.19M	N/A	N/A	20	Earnings Report
KEQU Kewaunee Scientific	1.3586 of 5 stars	$37.32 +3.1%	N/A	-35.9%	$107.03M	$282.00M	11.59	1,231	Gap Down
LUNG Pulmonx	2.5607 of 5 stars	$2.28 +0.7%	$7.67 +237.0%	+44.0%	$97.71M	$87.44M	N/A	250
OM Outset Medical	2.7757 of 5 stars	$4.73 -1.9%	$10.00 +111.4%	-64.5%	$88.91M	$117.80M	N/A	520	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAT) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartBeam (BEAT) Competitors

BEAT vs. MBOT, KEQU, LUNG, OM, and HYPR

How does HeartBeam compare to Microbot Medical?

Summary

How does HeartBeam compare to Kewaunee Scientific?

Summary

How does HeartBeam compare to Pulmonx?

Summary

How does HeartBeam compare to Outset Medical?

Summary

How does HeartBeam compare to Hyperfine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartBeam (BEAT) Competitors

BEAT vs. MBOT, KEQU, LUNG, OM, and HYPR

How does HeartBeam compare to Microbot Medical?

Does the media refer more to MBOT or BEAT?

Which has more volatility & risk, MBOT or BEAT?

Do analysts prefer MBOT or BEAT?

Which has better earnings & valuation, MBOT or BEAT?

Is MBOT or BEAT more profitable?

Do institutionals and insiders hold more shares of MBOT or BEAT?

Summary

How does HeartBeam compare to Kewaunee Scientific?

Do insiders and institutionals believe in BEAT or KEQU?

Which has preferable earnings & valuation, BEAT or KEQU?

Is BEAT or KEQU more profitable?

Do analysts rate BEAT or KEQU?

Which has more risk & volatility, BEAT or KEQU?

Does the media prefer BEAT or KEQU?

Summary

How does HeartBeam compare to Pulmonx?

Is LUNG or BEAT more profitable?

Does the media favor LUNG or BEAT?

Do insiders & institutionals hold more shares of LUNG or BEAT?

Do analysts rate LUNG or BEAT?

Which has more risk and volatility, LUNG or BEAT?

Which has stronger earnings & valuation, LUNG or BEAT?

Summary

How does HeartBeam compare to Outset Medical?

Which has more volatility and risk, OM or BEAT?

Does the media favor OM or BEAT?

Do insiders and institutionals have more ownership in OM or BEAT?

Do analysts recommend OM or BEAT?

Which has better earnings and valuation, OM or BEAT?

Is OM or BEAT more profitable?

Summary

How does HeartBeam compare to Hyperfine?

Is HYPR or BEAT more profitable?

Do insiders and institutionals have more ownership in HYPR or BEAT?

Does the media favor HYPR or BEAT?

Which has more risk & volatility, HYPR or BEAT?

Do analysts recommend HYPR or BEAT?

Which has higher valuation & earnings, HYPR or BEAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools